{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:51:46Z","timestamp":1787237506034,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":3841,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1111\/j.1523-1755.2005.09505.x","type":"journal-article","created":{"date-parts":[[2005,5,6]],"date-time":"2005-05-06T13:58:47Z","timestamp":1115387927000},"page":"S33-S36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"S95","title":["Calcimimetics: A new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease"],"prefix":"10.1016","volume":"67","author":[{"given":"Jill S.","family":"Lindberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.semnephrol.2003.08.020","article-title":"Production metabolic bone disease","volume":"24","author":"Lindberg","year":"2004","journal-title":"Semin Nephrol"},{"issue":"Suppl 3","key":"10.1111\/j.1523-1755.2005.09505.x_bb0015","first-page":"1","article-title":"K\/DOQI clinical practice guidelines on bone metabolism and disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0020","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/ndt\/17.5.723","article-title":"Management of disturbances of calcium and phosphate metabolism and chronic renal insufficiency with emphasis on the control of hyperphosphatemia","volume":"17","author":"Locatelli","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ndt\/17.2.204","article-title":"Calcimimetic agents and secondary hyperparathyroidism treatment and prevention","volume":"17","author":"Goodman","year":"2002","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 5","key":"10.1111\/j.1523-1755.2005.09505.x_bb0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ndt\/gfh1053","article-title":"Clinical experience with cinacalcet HCl","volume":"19","author":"Torres","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0035","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1046\/j.1523-1755.2000.00837.x","article-title":"Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism","volume":"57","author":"Wadam","year":"2000","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0040","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1172\/JCI119851","article-title":"The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor","volume":"100","author":"Wadam","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0045","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.1523-1755.1998.00782.x","article-title":"NPS R-568 halts or reverses osteoitis fibrosis in uremic rats","volume":"53","author":"Wadam","year":"1997","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1046\/j.1523-1755.1998.00735.x","article-title":"A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication","volume":"53","author":"Antonsen","year":"1998","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0055","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1523-1755.2000.00183.x","article-title":"A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism","volume":"58","author":"Goodman","year":"2000","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0060","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0022-3565(24)34924-9","article-title":"NPS R-568: A type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium","volume":"290","author":"Fox","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0065","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"Calcimimetic agent AMG 073 lowers parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0070","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","article-title":"Calcimimetic AMG 073 reduces parathyroid hormone in calcium \u00d7 phosphate in secondary hyperparathyroidism","volume":"63","author":"Lindberg","year":"2003","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0075","first-page":"764A","article-title":"Short-term treatment of secondary hyperparathyroidism (SHPT) with the calcimimetic agent AMG 073","volume":"12","author":"Drueke","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0080","series-title":"on behalf of the AMG 073 study groups IV Symposium Avances en Osteodistrofia Renal Oveido, June 6\u20137","author":"Cunningham","year":"2002"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0085","first-page":"461A","article-title":"Oral cinacalcet HCl (AMG 073) for the treatment of hemodialysis patients with secondary hyperparathyroidism, results of a European\/Australian phase 3 study","volume":"14","author":"de Francisco","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0090","first-page":"1520","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Brach","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0095","first-page":"36A","article-title":"Phase 3 experience with cinacalcet HCl and hemodialysis and peritoneal dialysis patients with secondary hyperparathyroidism","volume":"14","author":"Lindberg","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0100","first-page":"572A","article-title":"Two-year treatment with the calcimimetic AMG 073 in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Moe","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0105","first-page":"462A","article-title":"Pharmacokinetics (PK), pharmacodynamics (PD), and safety of daily administration of cinacalcet HCl up to 300 mg in chronic kidney disease (CKD) patients on hemodialysis (HD)","volume":"14","author":"Harris","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2005.09505.x_bb0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.semnephrol.2003.08.017","article-title":"Calcium-sensing receptors","volume":"24","author":"Goodman","year":"2004","journal-title":"Semin Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815508053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815508053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:45:18Z","timestamp":1758761118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815508053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":21,"alternative-id":["S0085253815508053"],"URL":"https:\/\/doi.org\/10.1111\/j.1523-1755.2005.09505.x","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcimimetics: A new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1523-1755.2005.09505.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}